Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision Both sides next revision
covid:unpublished [2020/06/02 13:55]
biogridadmin
covid:unpublished [2020/07/02 16:05]
biogridadmin
Line 9: Line 9:
 |  **888800000001** ​ |  **[[https://​doi.org/​10.1101/​2020.03.22.002386|10.1101/​2020.03.22.002386]]** ​ |  Gordon DE (2020) ​ | **[[https://​thebiogrid.org/​220839/​publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** ​ | |  **888800000001** ​ |  **[[https://​doi.org/​10.1101/​2020.03.22.002386|10.1101/​2020.03.22.002386]]** ​ |  Gordon DE (2020) ​ | **[[https://​thebiogrid.org/​220839/​publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** ​ |
 |  **888800000002** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.20041962|10.1101/​2020.03.29.20041962]]** ​ |  Gao T (2020) ​ | **[[https://​thebiogrid.org/​221112/​publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** ​ | |  **888800000002** ​ |  **[[https://​doi.org/​10.1101/​2020.03.29.20041962|10.1101/​2020.03.29.20041962]]** ​ |  Gao T (2020) ​ | **[[https://​thebiogrid.org/​221112/​publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** ​ |
-|  **888800000003** ​ |  **[[https://​doi.org/​10.1101/​2020.02.16.951723|10.1101/​2020.02.16.951723]]** ​ |  ​Xie L (2020) ​ | **[[https://​thebiogrid.org/​221178/​publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** ​ |+|  **888800000003** ​ |  **[[https://​doi.org/​10.1101/​2020.02.16.951723|10.1101/​2020.02.16.951723]]** ​ |  ​Sun C (2020) ​ | **[[https://​thebiogrid.org/​221178/​publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** ​ |
 |  **888800000004** ​ |  **[[https://​doi.org/​10.1101/​2020.03.16.994236|10.1101/​2020.03.16.994236]]** ​ |  Procko E (2020) ​ | **[[https://​thebiogrid.org/​221182/​publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]**  | |  **888800000004** ​ |  **[[https://​doi.org/​10.1101/​2020.03.16.994236|10.1101/​2020.03.16.994236]]** ​ |  Procko E (2020) ​ | **[[https://​thebiogrid.org/​221182/​publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]**  |
 |  **888800000005** ​ |  **[[https://​doi.org/​10.1101/​2020.03.14.988345|10.1101/​2020.03.14.988345]]** ​ |  Wang K (2020) ​ | **[[https://​thebiogrid.org/​221183/​publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** ​ | |  **888800000005** ​ |  **[[https://​doi.org/​10.1101/​2020.03.14.988345|10.1101/​2020.03.14.988345]]** ​ |  Wang K (2020) ​ | **[[https://​thebiogrid.org/​221183/​publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** ​ |
 
covid/unpublished.txt · Last modified: 2020/08/05 13:15 by biogridadmin